155 related articles for article (PubMed ID: 33161783)
41. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
42. [Current diagnosis and treatment for pediatric acute myeloid leukemia].
Shiba N
Rinsho Ketsueki; 2017; 58(4):389-399. PubMed ID: 28484171
[TBL] [Abstract][Full Text] [Related]
43. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
44. FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups.
Mały E; Przyborsk M; Nowak T; Nowak J; Januszkiewicz D
Postepy Hig Med Dosw (Online); 2010 Oct; 64():466-70. PubMed ID: 20966504
[TBL] [Abstract][Full Text] [Related]
45. [Molecular Features and Clinical Significance of Acute Myeloid Leukemia in Elderly Patients].
Wang BH; Guan W; Lyu N; Jin XS; Li T; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1445-1450. PubMed ID: 33067935
[TBL] [Abstract][Full Text] [Related]
46. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
Haferlach C; Dicker F; Herholz H; Schnittger S; Kern W; Haferlach T
Leukemia; 2008 Aug; 22(8):1539-41. PubMed ID: 18528419
[TBL] [Abstract][Full Text] [Related]
47. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of
Park DJ; Kwon A; Cho BS; Kim HJ; Hwang KA; Kim M; Kim Y
Blood Res; 2020 Mar; 55(1):17-26. PubMed ID: 32269971
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
50. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
[TBL] [Abstract][Full Text] [Related]
51. Distribution of Chromosomal Abnormalities Commonly Observed in Adult Acute Myeloid Leukemia in Pakistan as Predictors of Prognosis.
Shaikh MS; Ahmed ZA; Shaikh MU; Adil SN; Khurshid M; Moatter T; Rashid A; Karim F; Raheem A; Ali N
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1903-1906. PubMed ID: 30049204
[TBL] [Abstract][Full Text] [Related]
52. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
53. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
54. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
[TBL] [Abstract][Full Text] [Related]
55. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
56. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
57. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
Han TJ; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
[TBL] [Abstract][Full Text] [Related]
58. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
59. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.
Ghanem H; Tank N; Tabbara IA
Am J Hematol; 2012 Jan; 87(1):69-77. PubMed ID: 22072438
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]